Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 13/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4916061 | 0.95 | PTGER1 (0.64) | PTGER1SMN1; SMN2THRBS1PR4LMNA | |
| SCHEMBL4914148 | 0.91 | PTGER1 (0.67) | PTGER1SMN1; SMN2S1PR4LMNAGAA | |
| SCHEMBL4926019 | 0.89 | PTGER1 (0.67) | PTGER1SMN1; SMN2S1PR4LMNAGAA | |
| SCHEMBL4915784 | 0.87 | PTGER1 (0.74) | PTGER1SMN1; SMN2GAAMAPTALDH1A1 | |
| SCHEMBL14035056 | 0.87 | S1PR4 (0.51) | PTGER1SMN1; SMN2THRBS1PR4LMNA | |
| SCHEMBL4925385 | 0.85 | PTGER1 (0.70) | PTGER1SMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL4923036 | 0.85 | PTGER1 (0.61) | PTGER1SMN1; SMN2S1PR4LMNAGAA | |
| SCHEMBL4928961 | 0.84 | PTGER1 (0.72) | PTGER1GAA | |
| SCHEMBL4920186 | 0.83 | PTGER1 (0.71) | PTGER1LMNAALDH1A1 | |
| SCHEMBL4927464 | 0.83 | PTGER1 (0.77) | PTGER1SMN1; SMN2THRBLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | PTGER1, PTGER2, PTGER3 | PTGER1 1/4885SMN1; SMN2 3450/4885THRB 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.